| Year |
Citation |
Score |
| 2023 |
Yom-Tov E, Navar I, Fraenkel E, Berry JD. Identifying amyotrophic lateral sclerosis through interactions with an internet search engine. Muscle & Nerve. PMID 37877320 DOI: 10.1002/mus.27991 |
0.321 |
|
| 2023 |
Genge A, van den Berg LH, Frick G, Han S, Abikoff C, Simmons A, Lin Q, Patra K, Kupperman E, Berry JD. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. Jama Neurology. PMID 37695623 DOI: 10.1001/jamaneurol.2023.2851 |
0.338 |
|
| 2023 |
Raymond J, Punjani R, Larson T, Berry JD, Horton DK, Mehta P. Comparing Amyotrophic lateral sclerosis (ALS) patient characteristics from the National ALS Registry and the Massachusetts ALS Registry, data through 2015. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-8. PMID 37539949 DOI: 10.1080/21678421.2023.2239301 |
0.407 |
|
| 2023 |
Bouvier L, Green JR, Tapia CB, Tilton-Bolowsky V, Maffei MF, Fless Z, Seaver K, Huynh A, Gutz SE, Martino R, Abrahao A, Berry J, Zinman L, Yunusova Y. Amyotrophic Lateral Sclerosis-Bulbar Dysfunction Index-Remote: Test-Retest and Interrater Reliability of Candidate Items. American Journal of Speech-Language Pathology. 1-17. PMID 37494887 DOI: 10.1044/2023_AJSLP-22-00177 |
0.504 |
|
| 2023 |
Rush CL, Lester EG, Manglani H, Woodworth E, Vitolo O, Fava M, Berry JD, Brizzi K, Babu S, Lindenberger EC, Curtis JR, Vranceanu AM. Resilient together-ALS: leveraging the NDD transdiagnostic framework to develop an early dyadic intervention for people with amyotrophic lateral sclerosis and their informal care-partners. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-8. PMID 37345437 DOI: 10.1080/21678421.2023.2224400 |
0.348 |
|
| 2023 |
Quintana M, Saville BR, Vestrucci M, Detry MA, Chibnik L, Shefner J, Berry JD, Chase M, Andrews J, Sherman AV, Yu H, Drake K, Cudkowicz M, Paganoni S, Macklin EA. Design and Statistical Innovations in a Platform Trial for ALS. Annals of Neurology. PMID 37245090 DOI: 10.1002/ana.26714 |
0.32 |
|
| 2023 |
Yerton M, Winter A, Gelevski D, Addy G, Kostov A, Lieberman C, Weber H, Doyle M, Kane G, Cohen C, Parikh N, Burke KM, Rohrer M, Stirrat T, Bruno M, ... ... Berry JD, et al. Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS). Muscle & Nerve. PMID 36929648 DOI: 10.1002/mus.27819 |
0.323 |
|
| 2023 |
Johnson SA, Karas M, Burke KM, Straczkiewicz M, Scheier ZA, Clark AP, Iwasaki S, Lahav A, Iyer AS, Onnela JP, Berry JD. Wearable device and smartphone data quantify ALS progression and may provide novel outcome measures. Npj Digital Medicine. 6: 34. PMID 36879025 DOI: 10.1038/s41746-023-00778-y |
0.361 |
|
| 2023 |
Walk D, Nicholson K, Locatelli E, Chan J, Macklin EA, Ferment V, Manousakis G, Chase M, Connolly M, Dagostino D, Hall M, Ostrow J, Pothier L, Lieberman C, Gelevski D, ... ... Berry JD, et al. Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. Muscle & Nerve. PMID 36840949 DOI: 10.1002/mus.27807 |
0.315 |
|
| 2023 |
Maffei MF, Green JR, Murton O, Yunusova Y, Rowe HP, Wehbe F, Diana K, Nicholson K, Berry JD, Connaghan KP. Acoustic Measures of Dysphonia in Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research : Jslhr. 1-16. PMID 36802910 DOI: 10.1044/2022_JSLHR-22-00363 |
0.545 |
|
| 2023 |
Irwin KE, Jasin P, Braunstein KE, Sinha I, Bowden KD, Moghekar A, Oh ES, Raitcheva D, Bartlett D, Berry JD, Traynor B, Ling JP, Wong PC. A fluid biomarker reveals loss of TDP-43 splicing repression in pre-symptomatic ALS. Biorxiv : the Preprint Server For Biology. PMID 36789434 DOI: 10.1101/2023.01.23.525202 |
0.335 |
|
| 2023 |
Yunusova Y, Waito A, Barnett Tapia C, Huynh A, Martino R, Abrahao A, Pattee GL, Berry JD, Zinman L, Green JR. Face and content validation of the amyotrophic lateral sclerosis-Bulbar dysfunction index (ALS-BDI). Frontiers in Neurology. 13: 1078612. PMID 36686519 DOI: 10.3389/fneur.2022.1078612 |
0.6 |
|
| 2022 |
Ramamoorthy D, Severson K, Ghosh S, Sachs K, Glass JD, Fournier CN, Herrington TM, Berry JD, Ng K, Fraenkel E. Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data. Nature Computational Science. 2: 605-616. PMID 38177466 DOI: 10.1038/s43588-022-00299-w |
0.322 |
|
| 2022 |
Rowe HP, Gochyyev P, Lammert AC, Lowit A, Spencer KA, Dickerson BC, Berry JD, Green JR. The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates. Journal of Neural Transmission (Vienna, Austria : 1996). 129: 1487-1511. PMID 36305960 DOI: 10.1007/s00702-022-02550-0 |
0.549 |
|
| 2022 |
Mehta P, Raymond J, Han M, Punjani R, Larson T, Berry JD, Brooks BR, Oskarrson B, Goutman S, Horton K. A revision to the United States national ALS registry's algorithm to improve Case-Ascertainment. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-7. PMID 36194072 DOI: 10.1080/21678421.2022.2121168 |
0.385 |
|
| 2022 |
Eshghi M, Yunusova Y, Connaghan KP, Perry BJ, Maffei MF, Berry JD, Zinman L, Kalra S, Korngut L, Genge A, Dionne A, Green JR. Rate of speech decline in individuals with amyotrophic lateral sclerosis. Scientific Reports. 12: 15713. PMID 36127362 DOI: 10.1038/s41598-022-19651-1 |
0.573 |
|
| 2022 |
Johnson SA, Fang T, De Marchi F, Neel D, Van Weehaeghe D, Berry JD, Paganoni S. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents. Drugs. PMID 36121612 DOI: 10.1007/s40265-022-01769-1 |
0.424 |
|
| 2022 |
Salomon-Zimri S, Pushett A, Russek-Blum N, Van Eijk RPA, Birman N, Abramovich B, Eitan E, Elgrart K, Beaulieu D, Ennist DL, Berry JD, Paganoni S, Shefner JM, Drory VE. Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-9. PMID 36106817 DOI: 10.1080/21678421.2022.2119868 |
0.411 |
|
| 2022 |
Garcia-Montojo M, Simula ER, Fathi S, McMahan C, Ghosal A, Berry JD, Cudkowicz M, Elkahloun A, Johnson K, Norato G, Jensen P, James T, Sechi LA, Nath A. Antibody Response to HML-2 May Be Protective in Amyotrophic Lateral Sclerosis. Annals of Neurology. PMID 36053951 DOI: 10.1002/ana.26466 |
0.331 |
|
| 2022 |
Brooks BR, Berry JD, Ciepielewska M, Liu Y, Zambrano GS, Zhang J, Hagan M. Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis. Eclinicalmedicine. 52: 101590. PMID 35958519 DOI: 10.1016/j.eclinm.2022.101590 |
0.331 |
|
| 2022 |
Johnson SA, Burke KM, Scheier ZA, Keegan MA, Clark AP, Chan J, Fournier CN, Berry JD. Longitudinal comparison of the self-entry amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-RSE) and rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis. Muscle & Nerve. PMID 35904151 DOI: 10.1002/mus.27691 |
0.336 |
|
| 2022 |
Gutz SE, Stipancic KL, Yunusova Y, Berry JD, Green JR. Validity of Off-the-Shelf Automatic Speech Recognition for Assessing Speech Intelligibility and Speech Severity in Speakers With Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research : Jslhr. 65: 2128-2143. PMID 35623334 DOI: 10.1044/2022_JSLHR-21-00589 |
0.517 |
|
| 2022 |
Arredondo C, Cefaliello C, Dyrda A, Jury N, Martinez P, Díaz I, Amaro A, Tran H, Morales D, Pertusa M, Stoica L, Fritz E, Corvalán D, Abarzúa S, Méndez-Ruette M, ... ... Berry JD, et al. Excessive release of inorganic phosphate by ALS/FTD astrocytes causes non-cell-autonomous toxicity to motoneurons. Neuron. PMID 35276083 DOI: 10.1016/j.neuron.2022.02.010 |
0.372 |
|
| 2022 |
Yunusova Y, Waito A, Barnett C, Huynh A, Martino R, Abrahao A, Pattee GL, Berry JD, Zinman L, Green JR. Protocol for psychometric evaluation of the Amyotrophic Lateral Sclerosis - Bulbar Dysfunction Index (ALS-BDI): a prospective longitudinal study. Bmj Open. 12: e060102. PMID 35260465 DOI: 10.1136/bmjopen-2021-060102 |
0.595 |
|
| 2022 |
Tanchip C, Guarin DL, McKinlay S, Barnett C, Kalra S, Genge A, Korngut L, Green JR, Berry J, Zinman L, Yadollahi A, Abrahao A, Yunusova Y. Validating Automatic Diadochokinesis Analysis Methods Across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research : Jslhr. 1-14. PMID 35171700 DOI: 10.1044/2021_JSLHR-21-00503 |
0.398 |
|
| 2022 |
Baxi EG, Thompson T, Li J, Kaye JA, Lim RG, Wu J, Ramamoorthy D, Lima L, Vaibhav V, Matlock A, Frank A, Coyne AN, Landin B, Ornelas L, Mosmiller E, ... ... Berry J, et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nature Neuroscience. 25: 226-237. PMID 35115730 DOI: 10.1038/s41593-021-01006-0 |
0.339 |
|
| 2021 |
Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman A, Yu H, Drake K, Andrews J, Shefner J, Chibnik L, Vestrucci M, Cudkowicz ME, et al. Adaptive Platform Trials to Transform ALS Therapy Development. Annals of Neurology. PMID 34935174 DOI: 10.1002/ana.26285 |
0.359 |
|
| 2021 |
Mehta P, Raymond J, Han MK, Larson T, Berry JD, Paganoni S, Mitsumoto H, Bedlack RS, Horton DK. Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism. Journal of Medical Internet Research. 23: e28021. PMID 34878988 DOI: 10.2196/28021 |
0.38 |
|
| 2021 |
Petrozziello T, Amaral AC, Dujardin S, Farhan SMK, Chan J, Trombetta BA, Kivisäkk P, Mills AN, Bordt EA, Kim SE, Dooley PM, Commins C, Connors TR, Oakley DH, Ghosal A, ... ... Berry JD, et al. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. Brain Pathology (Zurich, Switzerland). e13035. PMID 34779076 DOI: 10.1111/bpa.13035 |
0.337 |
|
| 2021 |
Stipancic KL, Palmer KM, Rowe HP, Yunusova Y, Berry JD, Green JR. "You Say Severe, I Say Mild": Toward an Empirical Classification of Dysarthria Severity. Journal of Speech, Language, and Hearing Research : Jslhr. 1-18. PMID 34762814 DOI: 10.1044/2021_JSLHR-21-00197 |
0.525 |
|
| 2021 |
Eshghi M, Connaghan KP, Gutz SE, Berry JD, Yunusova Y, Green JR. Co-Occurrence of Hypernasality and Voice Impairment in Amyotrophic Lateral Sclerosis: Acoustic Quantification. Journal of Speech, Language, and Hearing Research : Jslhr. 1-12. PMID 34714698 DOI: 10.1044/2021_JSLHR-21-00123 |
0.549 |
|
| 2021 |
Berry J, Brooks B, Genge A, Heiman-Patterson T, Appel S, Benatar M, Bowser R, Cudkowicz M, Gooch C, Shefner J, Westra J, Agnese W, Merrill C, Nelson S, Apple S. Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology. Clinical Practice. 11: e472-e479. PMID 34476128 DOI: 10.1212/CPJ.0000000000000968 |
0.396 |
|
| 2021 |
Beaulieu D, Berry JD, Paganoni S, Glass JD, Fournier C, Cuerdo J, Schactman M, Ennist DL. Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 22: 22-32. PMID 34348539 DOI: 10.1080/21678421.2021.1924207 |
0.32 |
|
| 2021 |
Quinn C, Mcmillan CT, Owegi MA, Almasy K, Douthwright C, Mckenna-Yasek D, Goyal NA, Berry J, Brown RH. Single breath counting is an effective screening tool for forced vital capacity in ALS. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 22: 5-8. PMID 34348533 DOI: 10.1080/21678421.2021.1915337 |
0.31 |
|
| 2021 |
Stipancic KL, Yunusova Y, Campbell TF, Wang J, Berry JD, Green JR. Two Distinct Clinical Phenotypes of Bulbar Motor Impairment in Amyotrophic Lateral Sclerosis. Frontiers in Neurology. 12: 664713. PMID 34220673 DOI: 10.3389/fneur.2021.664713 |
0.566 |
|
| 2021 |
De Marchi F, Munitic I, Amedei A, Berry JD, Feldman EL, Aronica E, Nardo G, Van Weehaeghe D, Niccolai E, Prtenjaca N, Sakowski SA, Bendotti C, Mazzini L. Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. Neuroscience and Biobehavioral Reviews. 127: 958-978. PMID 34153344 DOI: 10.1016/j.neubiorev.2021.06.027 |
0.373 |
|
| 2021 |
Babu S, Hightower BG, Chan J, Zürcher NR, Kivisäkk P, Tseng CJ, Sanders DL, Robichaud A, Banno H, Evora A, Ashokkumar A, Pothier L, Paganoni S, Chew S, Dojillo J, ... ... Berry JD, et al. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. Neuroimage. Clinical. 30: 102672. PMID 34016561 DOI: 10.1016/j.nicl.2021.102672 |
0.337 |
|
| 2020 |
Nicholson K, Bjornevik K, Abu-Ali G, Chan J, Cortese M, Dedi B, Jeon M, Xavier R, Huttenhower C, Ascherio A, Berry JD. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-9. PMID 33135936 DOI: 10.1080/21678421.2020.1828475 |
0.355 |
|
| 2020 |
Berry JD, Bedlack R, Mathews D, Agnese W, Apple S. Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-4. PMID 32838576 DOI: 10.1080/21678421.2020.1804939 |
0.471 |
|
| 2020 |
Mueller C, Berry JD, McKenna-Yasek DM, Gernoux G, Owegi MA, Pothier LM, Douthwright CL, Gelevski D, Luppino SD, Blackwood M, Wightman NS, Oakley DH, Frosch MP, Flotte TR, Cudkowicz ME, et al. Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. The New England Journal of Medicine. 383: 151-158. PMID 32640133 DOI: 10.1056/Nejmoa2005056 |
0.331 |
|
| 2020 |
Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH, Ladha SS, Lacomis D, Harris JM, Scearce-Levie K, Ho C, Bowser R, Berry JD. Longitudinal biomarkers in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. PMID 32515902 DOI: 10.1002/Acn3.51078 |
0.43 |
|
| 2020 |
Andrews JA, Berry JD, Baloh RH, Carberry N, Cudkowicz ME, Dedi B, Glass J, Maragakis NJ, Miller TM, Paganoni S, Rothstein JD, Shefner JM, Simmons Z, Weiss MD, Bedlack RS. Amyotrophic Lateral Sclerosis Care and Research in the USA During the COVID-19 Pandemic: Challenges and Opportunities. Muscle & Nerve. PMID 32445195 DOI: 10.1002/Mus.26989 |
0.451 |
|
| 2020 |
Brizzi KT, Bridges JFP, Yersak J, Balas C, Thakur N, Galvin M, Hardiman O, Heatwole C, Ravits J, Simmons Z, Bruijn L, Chan J, Bedlack R, Berry JD. Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-9. PMID 32396393 DOI: 10.1080/21678421.2020.1760889 |
0.408 |
|
| 2020 |
Petrozziello T, Mills AN, Farhan SMK, Mueller KA, Granucci EJ, Glajch KE, Chan J, Chew S, Berry JD, Sadri-Vakili G. Lipocalin-2 is increased in amyotrophic lateral sclerosis. Muscle & Nerve. PMID 32369618 DOI: 10.1002/Mus.26911 |
0.407 |
|
| 2020 |
Barnett C, Green JR, Marzouqah R, Stipancic KL, Berry JD, Korngut L, Genge A, Shoesmith C, Briemberg H, Abrahao A, Kalra S, Zinman L, Yunusova Y. Reliability and validity of speech & pause measures during passage reading in ALS. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 21: 42-50. PMID 32138555 DOI: 10.1080/21678421.2019.1697888 |
0.648 |
|
| 2020 |
De Marchi F, Berry JD, Chan J, Caldwell S, Ellrodt A, Scalia J, Burke K, Fang T, Clark Sisodia R, Schwamm LH, Moura LMVR, Paganoni S. Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis. Journal of Neurology. PMID 32125520 DOI: 10.1007/S00415-020-09774-8 |
0.439 |
|
| 2020 |
Goyal NA, Berry JD, Windebank A, Nathan P, Maragakis NJ, van den Berg LH, Genge A, Miller R, Baloh RH, Kern R, Gothelf Y, Lebovits C, Cudkowicz M. Addressing Heterogeneity in Als Clinical Trials. Muscle & Nerve. PMID 31899540 DOI: 10.1002/Mus.26801 |
0.511 |
|
| 2019 |
Agurto C, Ahmad O, Cecchi GA, Norel R, Pietrowicz M, Eyigoz EK, Mosmiller E, Baxi E, Rothstein JD, Roy P, Berry J, Maragakis NJ. Analyzing progression of motor and speech impairment in ALS. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2019: 6097-6102. PMID 31947236 DOI: 10.1109/EMBC.2019.8857300 |
0.378 |
|
| 2019 |
Eshghi M, Stipancic KL, Mefferd A, Rong P, Berry JD, Yunusova Y, Green JR. Assessing Oromotor Capacity in ALS: The Effect of a Fixed-Target Task on Lip Biomechanics. Frontiers in Neurology. 10: 1288. PMID 31866935 DOI: 10.3389/Fneur.2019.01288 |
0.501 |
|
| 2019 |
Granucci EJ, Griciuc A, Mueller KA, Mills AN, Le H, Dios AM, McGinty D, Pereira J, Elmaleh D, Berry JD, Paganoni S, Cudkowicz ME, Tanzi RE, Sadri-Vakili G. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1 Mouse Model of amyotrophic lateral sclerosis. Scientific Reports. 9: 17728. PMID 31776380 DOI: 10.1038/S41598-019-53982-W |
0.327 |
|
| 2019 |
Berry JD, Cudkowicz ME, Windebank AJ, Staff NP, Owegi M, Nicholson K, McKenna-Yasek D, Levy YS, Abramov N, Kaspi H, Mehra M, Aricha R, Gothelf Y, Brown RH. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. PMID 31740545 DOI: 10.1212/Wnl.0000000000008620 |
0.397 |
|
| 2019 |
Dios AM, Babu S, Granucci EJ, Mueller KA, Mills AN, Alshikho MJ, Zürcher NR, Cernasov P, Gilbert TM, Glass JD, Berry JD, Atassi N, Hooker JM, Sadri-Vakili G. Class I and II HDAC expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and PET molecular neuroimaging evidence. Muscle & Nerve. PMID 31241177 DOI: 10.1002/Mus.26620 |
0.422 |
|
| 2019 |
Brizzi K, Paganoni S, Zehm A, De Marchi F, Berry JD. Integration of a Palliative Care Specialist in ALS Clinic: Observations from one Center. Muscle & Nerve. PMID 31172537 DOI: 10.1002/Mus.26607 |
0.32 |
|
| 2019 |
Wills AM, Garry J, Hubbard J, Mezoian T, Breen CT, Ortiz-Miller C, Nalipinski P, Sullivan S, Berry JD, Cudkowicz M, Paganoni S, Chan J, Macklin EA. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. Bmc Neurology. 19: 104. PMID 31142272 DOI: 10.1186/S12883-019-1330-6 |
0.434 |
|
| 2019 |
Berry JD, Paganoni S, Carlson K, Burke K, Weber H, Staples P, Salinas J, Chan J, Green JR, Connaghan K, Barback J, Onnela JP. Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. Annals of Clinical and Translational Neurology. 6: 873-881. PMID 31139685 DOI: 10.1002/Acn3.770 |
0.637 |
|
| 2019 |
Paganoni S, Van De Rijn M, Drake K, Burke K, Doyle M, Ellrodt AS, Nicholson K, Atassi N, De Marchi F, Babu S, Estrada J, Schwamm LH, Berry JD. Adjusted Cost Analysis of Video Televisits for the Care of People with ALS. Muscle & Nerve. PMID 31136007 DOI: 10.1002/Mus.26606 |
0.4 |
|
| 2019 |
Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. PMID 30926684 DOI: 10.1212/Wnl.0000000000007401 |
0.377 |
|
| 2019 |
van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. PMID 30850440 DOI: 10.1212/Wnl.0000000000007242 |
0.455 |
|
| 2019 |
Karam C, Berry JD. Heterogeneity, urgency, generalizability, and enrollment: The HUGE balance in ALS trials. Neurology. PMID 30626648 DOI: 10.1212/Wnl.0000000000006837 |
0.505 |
|
| 2019 |
Pattee GL, Plowman EK, Garand KLF, Costello J, Brooks BR, Berry JD, Smith RA, Atassi N, Chapin JL, Yunusova Y, McIlduff CE, Young E, Macklin EA, Locatelli ER, Silani V, et al. PROVISIONAL BEST PRACTICES GUIDELINES FOR THE EVALUATION OF BULBAR DYSFUNCTION IN ALS. Muscle & Nerve. PMID 30620104 DOI: 10.1002/Mus.26408 |
0.626 |
|
| 2019 |
Eshghi M, Connaghan K, Gutz S, Eshghi M, Berry J, Yunusova Y, Green J. Acoustic correlates of comorbid voice and resonance impairment in individuals with amyotrophic lateral sclerosis The Journal of the Acoustical Society of America. 146: 2923-2923. DOI: 10.1121/1.5137146 |
0.568 |
|
| 2018 |
Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, et al. Prediagnostic plasma branched chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. PMID 30429276 DOI: 10.1212/Wnl.0000000000006669 |
0.305 |
|
| 2018 |
Stipancic KL, Yunusova Y, Berry JD, Green JR. Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis. Journal of Speech, Language, and Hearing Research : Jslhr. 1-15. PMID 30383220 DOI: 10.1044/2018_Jslhr-S-17-0366 |
0.586 |
|
| 2018 |
Green JR, Allison KM, Cordella C, Richburg BD, Pattee GL, Berry JD, Macklin EA, Pioro EP, Smith RA. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in persons with ALS: A quantitative speech analysis. British Journal of Clinical Pharmacology. PMID 30152872 DOI: 10.1111/Bcp.13745 |
0.613 |
|
| 2018 |
Salter M, Corfield E, Ramadass A, Grand F, Green J, Westra J, Lim CR, Farrimond L, Feneberg E, Scaber J, Thompson A, Ossher L, Turner M, Talbot K, Cudkowicz M, ... Berry J, et al. Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. Ebiomedicine. PMID 29941342 DOI: 10.1016/J.Ebiom.2018.06.015 |
0.442 |
|
| 2018 |
Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurology(R) Neuroimmunology & Neuroinflammation. 5: e465. PMID 29845093 DOI: 10.1212/Nxi.0000000000000465 |
0.42 |
|
| 2018 |
Berry JD, Taylor AA, Beaulieu D, Meng L, Bian A, Andrews J, Keymer M, Ennist DL, Ravina B. Improved stratification of ALS clinical trials using predicted survival. Annals of Clinical and Translational Neurology. 5: 474-485. PMID 29687024 DOI: 10.1002/Acn3.550 |
0.394 |
|
| 2018 |
Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, ... ... Berry JD, et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 97: 1268-1283.e6. PMID 29566793 DOI: 10.1016/J.Neuron.2018.02.027 |
0.438 |
|
| 2018 |
Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, von Glehn F, Paul A, Diaz-Cruz C, Gholipour T, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Berry JD, Gandhi R. Correlating serum microRNAs and clinical parameters in Amyotrophic lateral sclerosis. Muscle & Nerve. PMID 29466830 DOI: 10.1002/Mus.26106 |
0.438 |
|
| 2018 |
Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-8. PMID 29308669 DOI: 10.1080/21678421.2017.1421666 |
0.477 |
|
| 2018 |
Conlon EG, Fagegaltier D, Agius P, Davis-Porada J, Gregory J, Hubbard I, Kang K, Kim D, Phatnani H, Kwan J, Sareen D, Broach JR, Simmons Z, Arcila-Londono X, Lee EB, ... ... Berry JD, et al. Author response: Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism Elife. DOI: 10.7554/Elife.37754.025 |
0.424 |
|
| 2018 |
Green J, Connaghan K, Yunusova Y, Stipancic K, Gutz S, Berry J. Vocal changes across disease progression in amyotrophic lateral sclerosis (ALS) The Journal of the Acoustical Society of America. 144: 1966-1966. DOI: 10.1121/1.5068594 |
0.645 |
|
| 2017 |
Van De Rijn M, Paganoni S, Levine-Weinberg M, Campbell K, Swartz Ellrodt A, Estrada J, Cohen AB, Schwamm LH, Berry JD. Experience with telemedicine in a multi-disciplinary ALS clinic. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-6. PMID 29250986 DOI: 10.1080/21678421.2017.1392577 |
0.399 |
|
| 2017 |
Pattee GL, Plowman EK, Brooks BR, Berry JD, Atassi N, Chapin JL, Garand K, Yunusova Y, Mcilduff CE, Young E, Costello JM, Macklin EA, Locatelli ER, Silani V, Heitzman D, et al. Best practices protocol for the evaluation of bulbar dysfunction: summary recommendations from the NEALS bulbar subcommittee symposium. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-2. PMID 29205054 DOI: 10.1080/21678421.2017.1404109 |
0.468 |
|
| 2017 |
Paganoni S, Nicholson K, Chan J, Shui A, Schoenfeld D, Sherman A, Berry J, Cudkowicz M, Atassi N. Urate Levels Predict Survival in ALS: Analysis of the Expanded PRO-ACT Database. Muscle & Nerve. PMID 28857199 DOI: 10.1002/Mus.25950 |
0.429 |
|
| 2017 |
Berry JD, Paganoni S, Atassi N, Macklin EA, Goyal N, Rivner M, Simpson E, Appel S, Grasso DL, Mejia NI, Mateen F, Gill A, Vieira F, Tassinari V, Perrin S. Phase IIA Trial of Fingolimod for ALS Demonstrates Acceptable Acute Safety and Tolerability. Muscle & Nerve. PMID 28662296 DOI: 10.1002/Mus.25733 |
0.418 |
|
| 2017 |
Gendron TF, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM, Pastor P, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Benatar M, Silani V, Glass JD, et al. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis. Annals of Neurology. PMID 28628244 DOI: 10.1002/Ana.24980 |
0.387 |
|
| 2017 |
Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O'Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, ... ... Berry JD, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Science Translational Medicine. 9. PMID 28356511 DOI: 10.1126/Scitranslmed.Aai7866 |
0.35 |
|
| 2017 |
Allison KM, Yunusova Y, Campbell TF, Wang J, Berry JD, Green JR. The diagnostic utility of patient-report and speech-language pathologists' ratings for detecting the early onset of bulbar symptoms due to ALS. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-9. PMID 28355886 DOI: 10.1080/21678421.2017.1303515 |
0.602 |
|
| 2017 |
Paganoni S, Macklin EA, Karam C, Yu H, Gonterman F, Fetterman KA, Cudkowicz M, Berry J, Wills AM. Vitamin D levels are associated with gross motor function in ALS. Muscle & Nerve. PMID 28044349 DOI: 10.1002/Mus.25555 |
0.366 |
|
| 2017 |
Aricha R, Cudkowicz M, Berry J, Windebank A, Staff N, Owegi M, Levy Y, Abramov N, Lebovits C, Brown R, Gothelf Y. In vivo modulation of neurotrophic and inflammatory factors in the CSF of ALS patients treated with NurOwn (MSC NTF cells) Cytotherapy. 19: S199. DOI: 10.1016/J.Jcyt.2017.02.297 |
0.368 |
|
| 2017 |
Gothelf Y, Cudkowicz M, Berry J, Windebank A, Staff N, Owegi M, Levy Y, Aricha R, Mehra M, Lebovits C, Brown R. Safety and efficacy of transplantation of nurown (autologous mesenchymal stromal cells secreting neurotrophic factors) in patients with ALS: A phase 2 randomized double blind placebo controlled trial Cytotherapy. 19: S23. DOI: 10.1016/J.Jcyt.2017.02.040 |
0.333 |
|
| 2016 |
Rong P, Yunusova Y, Wang J, Zinman L, Pattee GL, Berry JD, Perry B, Green JR. Predicting Speech Intelligibility Decline in Amyotrophic Lateral Sclerosis Based on the Deterioration of Individual Speech Subsystems. Plos One. 11: e0154971. PMID 27148967 DOI: 10.1371/Journal.Pone.0154971 |
0.513 |
|
| 2015 |
Ratti E, Berry JD, Greenblatt DJ, Loci L, Ellrodt AS, Shefner JM, Cudkowicz ME. Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone. Toxicology Reports. 2: 1396-1403. PMID 26705515 DOI: 10.1016/J.Toxrep.2015.09.010 |
0.31 |
|
| 2015 |
Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, Bruijn L. ALS Biomarkers for Therapy Development: State of the Field & Future Directions. Muscle & Nerve. PMID 26574709 DOI: 10.1002/Mus.24979 |
0.416 |
|
| 2015 |
Butovsky O, Jedrychowski MP, Cialic R, Murugaiyan G, Wu PM, Doykan CE, Fanek Z, Greco DJ, Kiner O, Lawson RJ, Frosch MP, Pochet N, Krichevsky AM, Gygi SP, Berry J, et al. Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 47: 5. PMID 26531345 DOI: 10.1016/J.Ijdevneu.2015.04.023 |
0.346 |
|
| 2015 |
Salameh JS, Brown RH, Berry JD. Amyotrophic Lateral Sclerosis: Review. Seminars in Neurology. 35: 469-76. PMID 26502769 DOI: 10.1055/S-0035-1558984 |
0.466 |
|
| 2015 |
Nicholson KA, Cudkowicz ME, Berry JD. Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 376-83. PMID 25700798 DOI: 10.1007/S13311-015-0341-2 |
0.41 |
|
| 2015 |
Shellikeri S, Yunusova Y, Green JR, Pattee GL, Berry JD, Rutkove SB, Zinman L. Electrical impedance myography in the evaluation of the tongue musculature in amyotrophic lateral sclerosis. Muscle & Nerve. PMID 25580728 DOI: 10.1002/Mus.24565 |
0.544 |
|
| 2015 |
Butovsky O, Jedrychowski MP, Cialic R, Krasemann S, Murugaiyan G, Fanek Z, Greco DJ, Wu PM, Doykan CE, Kiner O, Lawson RJ, Frosch MP, Pochet N, Fatimy RE, Krichevsky AM, ... ... Berry J, et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. Annals of Neurology. 77: 75-99. PMID 25381879 DOI: 10.1002/Ana.24304 |
0.301 |
|
| 2015 |
Zhu Y, Fotinos A, Mao LL, Atassi N, Zhou EW, Ahmad S, Guan Y, Berry JD, Cudkowicz ME, Wang X. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discovery Today. 20: 65-75. PMID 25205348 DOI: 10.1016/J.Drudis.2014.08.016 |
0.443 |
|
| 2014 |
Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh SY, Todd PK, Berry JD, et al. Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron. 84: 239. PMID 28898625 DOI: 10.1016/J.Neuron.2014.09.019 |
0.348 |
|
| 2014 |
Paganoni S, Cudkowicz M, Berry JD. Outcome measures in amyotrophic lateral sclerosis clinical trials. Clinical Investigation. 4: 605-618. PMID 28203356 DOI: 10.4155/Cli.14.52 |
0.47 |
|
| 2014 |
Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 83: 1719-25. PMID 25298304 DOI: 10.1212/Wnl.0000000000000951 |
0.485 |
|
| 2014 |
Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P, Johnston A, Overstreet K, Oh SY, Todd PK, Berry JD, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 83: 1043-50. PMID 25132468 DOI: 10.1016/J.Neuron.2014.07.041 |
0.306 |
|
| 2014 |
Schwartz JC, Podell ER, Han SS, Berry JD, Eggan KC, Cech TR. FUS is sequestered in nuclear aggregates in ALS patient fibroblasts. Molecular Biology of the Cell. 25: 2571-8. PMID 25009283 DOI: 10.1091/Mbc.E14-05-1007 |
0.361 |
|
| 2014 |
Lawton KA, Brown MV, Alexander D, Li Z, Wulff JE, Lawson R, Jaffa M, Milburn MV, Ryals JA, Bowser R, Cudkowicz ME, Berry JD. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15: 362-70. PMID 24984169 DOI: 10.3109/21678421.2014.908311 |
0.469 |
|
| 2014 |
Berry JD, Korngut L. Reevaluating the risk of DVT in people with ALS: weak in the knees and DVTs. Neurology. 82: 1668-9. PMID 24727310 DOI: 10.1212/Wnl.0000000000000420 |
0.457 |
|
| 2014 |
Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G, Berry JD, Brown RH, Cudkowicz ME, Bean BP, Eggan K, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Reports. 7: 1-11. PMID 24703839 DOI: 10.1016/J.Celrep.2014.03.019 |
0.388 |
|
| 2014 |
Berry JD, Cudkowicz ME, Shefner JM. Predicting success: optimizing phase II ALS trials for the transition to phase III. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15: 1-8. PMID 24588460 DOI: 10.3109/21678421.2013.838969 |
0.36 |
|
| 2014 |
Bucheli M, Andino A, Montalvo M, Cruz J, Atassi N, Berry J, Salameh J. Amyotrophic lateral sclerosis: analysis of ALS cases in a predominantly admixed population of Ecuador. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15: 106-13. PMID 24245684 DOI: 10.3109/21678421.2013.852590 |
0.443 |
|
| 2013 |
Bucheli ME, Calderón A, Chicaiza D, Franco C, López R, Digga E, Atassi N, Salameh J, Berry JD. Feedback interaction of research, advocacy, and clinical care applied to ALS research in South America. Neurology. 81: 1959-61. PMID 24276333 DOI: 10.1212/01.Wnl.0000436610.28210.A5 |
0.493 |
|
| 2013 |
Green JR, Yunusova Y, Kuruvilla MS, Wang J, Pattee GL, Synhorst L, Zinman L, Berry JD. Bulbar and speech motor assessment in ALS: challenges and future directions. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 494-500. PMID 23898888 DOI: 10.3109/21678421.2013.817585 |
0.605 |
|
| 2013 |
Quinn C, Macklin EA, Atassi N, Bowser R, Boylan K, Cudkowicz M, Fournier C, Ladha SS, Lacomis D, Berry J. Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 632-4. PMID 23834161 DOI: 10.3109/21678421.2013.808227 |
0.451 |
|
| 2013 |
Sherman AV, Gubitz AK, Al-Chalabi A, Bedlack R, Berry J, Conwit R, Harris BT, Horton DK, Kaufmann P, Leitner ML, Miller R, Shefner J, Vonsattel JP, Mitsumoto H. Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 53-61. PMID 23678880 DOI: 10.3109/21678421.2013.779058 |
0.477 |
|
| 2013 |
Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. Plos One. 8: e61177. PMID 23613806 DOI: 10.1371/Journal.Pone.0061177 |
0.326 |
|
| 2013 |
Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, Dong Y, Ingersoll EW, Archibald D. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 162-8. PMID 23323713 DOI: 10.3109/21678421.2012.762930 |
0.473 |
|
| 2013 |
Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14: 44-51. PMID 22985432 DOI: 10.3109/17482968.2012.723723 |
0.313 |
|
| 2012 |
Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, Lawson R, Berry J, Krichevsky AM, Cudkowicz ME, Weiner HL. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. The Journal of Clinical Investigation. 122: 3063-87. PMID 22863620 DOI: 10.1172/Jci62636 |
0.401 |
|
| 2012 |
Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, Costa J, Cudkowicz M, Glass J, Jahn O, Lehnert S, Malaspina A, Parnetti L, Petzold A, Shaw P, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 13: 1-10. PMID 22214350 DOI: 10.3109/17482968.2011.627589 |
0.469 |
|
| 2012 |
Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, Bowser R, Lawson R, Jaffa M, Milburn MV, Ryals JA, Berry JD. Biochemical alterations associated with ALS. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 13: 110-8. PMID 22117131 DOI: 10.3109/17482968.2011.619197 |
0.493 |
|
| 2012 |
Shefner J, Andrews J, Bedlack R, Berry J, Goslin K, Jackson C, Kissel J, Lange D, Licht J, Mozaffar T, Pestronk A, Rosenfeld J, Wolff A, Lee J, Masonek J, et al. A Study To Evaluate Safety and Tolerability of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily, Dose-Titration Regimen (P04.155) Neurology. 78: P04.155-P04.155. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.155 |
0.332 |
|
| 2012 |
Rudnicki S, Berry J, Ingersoll E, Archibald D, Cudkowicz M, Kerr D, Dong Y. Dexpramipexole Effects on Functional Decline in ALS Patients in a Phase II Study: Subgroup Analysis of Demographic and Clinical Characteristics (P04.149) Neurology. 78: P04.149-P04.149. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.149 |
0.35 |
|
| 2012 |
Butovsky O, Siddiqui S, Gabriely G, Lanser A, Dake B, Gopal M, Doykan C, Wu P, Lawson R, Berry J, Krichevsky A, Cudkowicz M, Weiner H. Identification of a Unique miRNA Signature in CD14+/CD16- Blood-Monocytes in ALS Subjects Identical to That Observed in SOD Mice (IN9-2.002) Neurology. 78: IN9-2.002-IN9-2.002. DOI: 10.1212/Wnl.78.1_Meetingabstracts.In9-2.002 |
0.361 |
|
| 2012 |
Nelson SK, Sterling D, Williams S, Lawson RJ, Berry JD, Cudkowicz ME. ALS Biomarker Discovery Using SOMAscan™ Multiplex Proteomic Technology Free Radical Biology and Medicine. 53: S69. DOI: 10.1016/J.Freeradbiomed.2012.10.209 |
0.397 |
|
| 2011 |
Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clinical Investigation. 1: 1375-1389. PMID 22545191 DOI: 10.4155/Cli.11.127 |
0.38 |
|
| Show low-probability matches. |